R. Srinivasa Iyengar has presented his views on William Shakespeare’s art of dramaturgy in noteworthy work; Shakespeare: His World and Art. It was published 1964 received enthusiastically by lovers literature. The work finally been divided into fifteen chapters. purpose present study is to discuss Iyengar’s view tragedy detail. love for the artistic sense cherished mother who fond literature sp...

Although the epidemiology and the impact of acute kidney injury on outcomes are well known in the western literature, good data is lacking from central India. Little is known about patients sustaining acute kidney injury (AKI) in the community acquired acute kidney injury (CAAKI) and how this differs from AKI in hospital acquired acute kidney injury (HAAKI). The objective of this study is to co...

The aim of this study was to formulate and evaluate zidovudine loaded chitosan microspheres for controlled drug release. Microspheres were prepared by emulsification method using gluteraldehyde as crosslinking agent. The prepared microspheres were characterized for their yield and drug loading, as well by Fourier transform infrared spectroscopy (FTIR), X-ray powder diffractometry and Scanning e...

The current HIV/AIDS scenario in India is quite grim with an estimated 2.4 million people living with HIV/AIDS (PLHA) in 2008, just behind South Africa and Nigeria. The anti-retroviral drugs (ARVs) remain the main stay of global HIV/AIDS treatment. Over 30 ARVs (single and FDCs) available under six categories viz., NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reve...

INTRODUCTION Controlled release oral dosage forms are in the focus of interest for several reasons. Customer compliance with the trend to simplicity and more comfort of use, the prolonged drug release with more reliable blood levels than those obtained with conventional dosage forms and life-cycle management of existing API’s directed the pharmaceutical development towards sustained release for...

Introduction: Epcoritamab, an off-the-shelf subcutaneous CD3xCD20 T-cell–engaging, bispecific antibody that redirects CD3+ T cells to eliminate malignant CD20+ B cells, has shown deep and durable responses in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patient populations, including those with difficult-to-treat LBCL. In the absence of head-to-head trials, there is a need assess comp...

Introduction: Many patients (pts) with B-cell malignancies require continuous treatment Bruton tyrosine kinase inhibitors (BTKi). Adverse events (AEs) are a common reason for ibrutinib (ibr) or acalabrutinib (acala) discontinuation. Early data from BGB-3111-215 showed zanubrutinib (zanu) was well tolerated in pts who were intolerant to either ibr acala. Here we report preliminary results of the...

Introduction: Most patients (pts) with LBCL respond to axi-cel, but many will eventually experience disease progression (Jacobson et al. JCO. 2020). Monitoring of ctDNA from blood, a minimally invasive diagnostic tool, has been used assess measurable residual (MRD) prognostic value, including in pts diffuse treated axi-cel the third line therapy (3L; Frank 2019). Here, we explored value predict...

Introduction: Up to 30–40% of pts with diffuse large BCL relapse/become refractory after first-line chemo-immunotherapy R-CHOP. CELMoD agent CC-99282 builds on the efficacy immunomodulatory agents by optimizing degradation target proteins Ikaros/Aiolos, enhancing antiproliferative and apoptotic activity; it showed a manageable safety profile promising clinical activity as monotherapy in relapse...